Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: A systematic review and meta-analysis

Psychological Medicine

Volumn 44, Issue 12, 2014, Pages 2475-2487

  Pollak, T A ^a,b   McCormack, R ^a,b   Peakman, M ^b,c   Nicholson, T R ^b   David, A S ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antibody; autoimmunity; N methyl d aspartate (NMDA) receptor; psychosis; schizophrenia

Indexed keywords

AUTOANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

HUMAN; IMMUNOLOGY; META ANALYSIS; PSYCHOSIS; SCHIZOPHRENIA;

AUTOANTIBODIES; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84904968553     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S003329171300295X     Document Type: Review

References (68)

1. Adams RA, Stephan KE, Brown HR, Frith CD, Friston KJ. (2013). The computational anatomy of psychosis. Frontiers in Psychiatry 4, 47.
2. Bamne M, Wood J, Chowdari K, Watson AM, Celik C, Mansour H, Klei L, Gur RC, Bradford LD, Calkins ME, Santos AB, Edwards N, Kwentus J, McEvoy JP, Allen TB, Savage RM, Nasrallah HA, Gur RE, Perry RT, Go RC, Devlin B, Yolken R, Nimgaonkar VL. (2012). Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. Schizophrenia Bulletin 38, 1149-1154.
3. Bechter K. (2013). Updating the mild encephalitis hypothesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 42, 71-91.
4. Benros ME, Mortensen PB, Eaton WW. (2012). Autoimmune diseases and infections as risk factors for schizophrenia. Annals of the New York Academy of Sciences 1262, 56-66.
5. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. (2011). Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. American Journal of Psychiatry 168, 1303-1310.
6. Blomstrom A, Karlsson H, Wicks S, Yang S, Yolken RH, Dalman C. (2012). Maternal antibodies to infectious agents and risk for non-Affective psychoses in the offspring-A matched case-control study. Schizophrenia Research 140, 25-30.
7. Bokesch PM, Izykenova GA, Justice JB, Easley KA, Dambinova SA. (2006). NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke 37, 1432-1436. (Pubitemid 44305722)
8. Cahalan S. (2012). Brain On Fire: My Month of Madness. Particular Books: London.
9. Carroll BT, Goforth HW, Thomas C, Ahuja N, McDaniel WW, Kraus MF, Spiegel DR, Franco KN, Pozuelo L, Munoz C. (2007). Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. Journal of Neuropsychiatry and Clinical Neurosciences 19, 406-412. (Pubitemid 350156098)
10. Choe CU, Karamatskos E, Schattling B, Leypoldt F, Liuzzi G, Gerloff C, Friese MA, Mulert C. (2013). A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Research 208, 194-196.
11. Corlett PR, Honey GD, Krystal JH, Fletcher PC. (2011). Glutamatergic model psychoses: Prediction error, learning, and inference. Neuropsychopharmacology 36, 294-315.
12. Correll CM. (2013). Antibodies in epilepsy. Current Neurology and Neuroscience Reports 13, 348.
13. Creten C, Van der Zwaan S, Blankespoor RJ, Maatkamp A, Nicolai J, Van Os J, Schieveld JN. (2011). Late onset autism and anti-NMDA-receptor encephalitis. Lancet 378, 98.
14. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. (2008). Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurology 7, 1091-1098.
15. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. (2007). Paraneoplastic anti-N-methyl-D-Aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology 61, 25-36. (Pubitemid 46214241)
16. Daniels J. (2009). Catatonia: Clinical aspects and neurobiological correlates. Journal of Neuropsychiatry and Clinical Neurosciences 21, 371-380.
17. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 169, 1203-1210.
18. Dickerson F, Stallings C, Origoni A, Vaughan C, Katsafanas E, Khushalani S, Yolken R. (2013). A combined marker of inflammation in individuals with mania. PLoS One 8, e73520.
19. Dickerson F, Stallings C, Vaughan C, Origoni A, Khushalani S, Yolken R. (2012). Antibodies to the glutamate receptor in mania. Bipolar Disorders 14, 547-553.
20. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM. (2012). Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37, 2515-2521.
21. Fink M. (2013). Rediscovering catatonia: The biography of a treatable syndrome. Acta Psychiatrica Scandinavica. Supplementum 441, 1-47.
22. Finke C, Kopp UA, Pruss H, Dalmau J, Wandinger KP, Ploner CJ. (2012). Cognitive deficits following anti-NMDA receptor encephalitis. Journal of Neurology, Neurosurgery and Psychiatry 83, 195-198.
23. Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, Siren AL, Pardo LA, Sperling S, Mohd Jofrry S, Gurvich A, Jensen N, Ostmeier K, Luhder F, Probst C, Martens H, Gillis M, Saher G, Assogna F, Spalletta G, Stocker W, Schulz TF, Nave KA, Ehrenreich H. (2013). Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Molecular Psychiatry. Published online: 3 September 2013. doi:10.1038/mp.2013.110.
24. Haussleiter IS, Emons B, Schaub M, Borowski K, Brune M, Wandinger KP, Juckel G. (2012). Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients. Schizophrenia Research 140, 258-259.
25. Henneberg AE, Horter S, Ruffert S. (1994). Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophrenia Research 14, 15-22. (Pubitemid 24372779)
26. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J, Balice-Gordon RJ. (2010). Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. Journal of Neuroscience 30, 5866-5875.
27. Irani SR, Bera K,Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A. (2010). N-methyl-d-Aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133, 1655-1667.
28. Kanbayashi T, Tsutsui K, Tanaka K, Boku S, Ito W, Imanishi A, Suda H, Takahashi J, Inomata Y, Takeshima M, Kosaka M, Yaegashi K, Yuasa W, Mori A, Nishino S, Takahashi Y, Shimizu T. (2012). Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. Paper presented at the 21st Congress of the European Sleep Research Society, Paris, France, 4-8 September 2012.
29. Kanbayashi T, Tsutsui K, Tanaka K, Ito W, Boku S, Sagawa Y, Tokunaga J, Sato M, Nishino S, Shimizu T. (2011). Anti-NMDA receptor antibody positive patients with various psychiatric and sleep symptoms. Paper presented at the Sleep and Biological Rhythms Conference, Worldsleep2011, Kyoto, Japan, 16-20 October 2011.
30. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. (2013). Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-Aspartate receptor encephalitis. Journal of the American Medical Association Neurology 70, 1133-1139.
31. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. (2012). Childhood infection and adult schizophrenia: A meta-Analysis of population-based studies. Schizophrenia Research 139, 161-168.
32. Khandaker GM, Zimbron J, Lewis G, Jones PB. (2013). Prenatal maternal infection, neurodevelopment and adult schizophrenia: A systematic review of population-based studies. Psychological Medicine 43, 239-257.
33. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N. (2011). A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. Journal of Clinical Psychopharmacology 31, 349-355.
34. Lancaster E, Dalmau J. (2012). Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nature Reviews. Neurology 8, 380-390.
35. Lauvsnes MB, Omdal R. (2012). Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. Journal of Neurology 259, 622-629.
36. Lennox BR, Coles AJ, Vincent A. (2012). Antibody-mediated encephalitis: A treatable cause of schizophrenia. British Journal of Psychiatry 200, 92-94.
37. Lennox BR, Deakin J, Zandi M, Scoriels L, Cox A, Coles A, Vincent A. (2013). Anti neuronal cell surface antibodies as a cause of schizophrenia. Schizophrenia Bulletin 39 (Suppl. 1), S1-S358. Abstracts for the 14th International Congress on Schizophrenia Research (ICOSR), S6.
38. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, Torrey EF, Yolken RH. (2004). Antibodies to infectious agents in individuals with recent onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 254, 4-8. (Pubitemid 39310542)
39. Liu J, Moghaddam B. (1995). Regulation of glutamate efflux by excitatory amino acid receptors: Evidence for tonic inhibitory and phasic excitatory regulation. Journal of Pharmacology and Experimental Therapeutics 274, 1209-1215.
40. Mackay G, Ahmad K, Stone J, Sudlow C, Summers D, Knight R, Will R, Irani SR, Vincent A, Maddison P. (2012). NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. Journal of Neurology 259, 1979-1981.
41. Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. (2010). In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: Further evidence of synaptic glutamatergic dysfunction. Orphanet Journal of Rare Diseases 5, 31.
42. Masdeu JC, Gonzalez-Pinto A, Matute C, Ruiz De Azua S, Palomino A, De Leon J, Berman KF, Dalmau J. (2012). Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. American Journal of Psychiatry 169, 1120-1121.
43. Moghaddam B, Adams BW. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352. (Pubitemid 28406826)
44. Moghaddam B, Javitt D. (2012). From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37, 4-15.
45. Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ. (2010). Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: Insights from molecular, cellular and synaptic studies. European Journal of Neuroscience 32, 298-309.
46. Muller N, Myint AM, Krause D, Weidinger E, Schwarz MJ. (2013). Anti-inflammatory treatment in schizophrenia. Progress in Neuro- Psychopharmacology and Biological Psychiatry 42, 146-153.
47. Na KS, Jung HY, Kim YK. (2012). The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. Published online: 1 November 2012. doi:10.1016/j.pnpbp.2012.10.022.
48. Northoff G. (2002). What catatonia can tell us about top-down modulation: A neuropsychiatric hypothesis. Behavioral and Brain Sciences 25, 555-577; discussion 578-604.
49. Obregon DF, Velasco RM, Wuerz TP, Catalano MC, Catalano G, Kahn D. (2011). Memantine and catatonia: A case report and literature review. Journal of Psychiatric Practice 17, 292-299.
50. Papanastasiou E, Stone JM, Shergill S. (2013). When the drugs dont work: The potential of glutamatergic antipsychotics in schizophrenia. British Journal of Psychiatry 202, 91-93.
51. Pollak TA, Lennox BR, Vincent A, Nicholson TR. (2012). Antibody-mediated encephalitis and psychosis. British Journal of Psychiatry 200, 344; author reply 344-345.
52. Pruss H, Holtje M, Maier N, Gomez A, Buchert R, Harms L, Ahnert-Hilger G, Schmitz D, Terborg C, Kopp U, Klingbeil C, Probst C, Kohler S, Schwab JM, Stoecker W, Dalmau J, Wandinger KP. (2012). IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 78, 1743-1753.
53. Punja M, Pomerleau AC, Devlin JJ, Morgan BW, Schier JG, Schwartz MD. (2013). Anti-N-methyl-D-Aspartate receptor (anti-NMDAR) encephalitis: An etiology worth considering in the differential diagnosis of delirium. Clinical Toxicology 51, 794-797.
54. Rhoads J, Guirgis H, McKnight C, Duchemin AM. (2011). Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophrenia Research 129, 213-214.
55. Ribbe K, Friedrichs H, Begemann M, Grube S, Papiol S, Kastner A, GerchenMF, AckermannV, Tarami A, Treitz A, Flogel M, Adler L, Aldenhoff JB, Becker-Emner M, Becker T, Czernik A, Dose M, Folkerts H, Freese R, Gunther R, Herpertz S, Hesse D, Kruse G, Kunze H, FranzM, Lohrer F, MaierW, Mielke A, Muller-Isberner R, Oestereich C, Pajonk FG, Pollmacher T, Schneider U, Schwarz HJ, Kroner-Herwig B, Havemann-Reinecke U, Frahm J, Stuhmer W, Falkai P, Brose N, Nave KA, Ehrenreich H. (2010). The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry 10, 91.
56. Rolls ET, Deco G. (2011). A computational neuroscience approach to schizophrenia and its onset. Neuroscience and Biobehavioral Reviews 35, 1644-1653.
57. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM. (2005). Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. American Journal of Psychiatry 162, 394-396. (Pubitemid 40216226)
58. Scott O, Richer L, Forbes K, Sonnenberg L, Currie A, Eliyashevska M, Goez HR. (2013). Anti-N-methyl-D-Aspartate (NMDA) receptor encephalitis: An unusual cause of autistic regression in a toddler. Journal of Child Neurology. Published online: 3 October 2013. doi:10.1177/0883073813501875.
59. Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, Kastner A, Skalej M, Jordan W, Schiltz K, Klingbeil C, Wandinger KP, Bogerts B, Stoecker W. (2013). Increased prevalence of diverse N-methyl-D-Aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: Specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-Aspartate glutamate receptor encephalitis. Journal of the American Medical Association Psychiatry 70, 271-278.
60. Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, Krystal JH, Nutt D, Barker GJ. (2012). Ketamine effects on brain GABA and glutamate levels with 1H-MRS: Relationship to ketamine-induced psychopathology. Molecular Psychiatry 17, 664-665.
61. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. (2013). Treatment and prognostic factors for long-Term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurology 12, 157-165.
62. Tsutsui K, Kanbayashi T, Tanaka K, Boku S, Ito W, Tokunaga J, Mori A, Hishikawa Y, Shimizu T, Nishino S. (2012). Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 12, 37.
63. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. (2005). Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Annals of Neurology 58, 594-604. (Pubitemid 41377223)
64. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. (2011). Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. Journal of Neuroimmunology 231, 86-91.
65. Weissman JD, Khunteev GA, Heath R, Dambinova SA. (2011). NR2 antibodies: Risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. Journal of the Neurological Sciences 300, 97-102.
66. Wright P, Nimgaonkar VL, Donaldson PT, Murray RM. (2001). Schizophrenia and HLA: A review. Schizophrenia Research 47, 1-12. (Pubitemid 32121766)
67. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR. (2011). Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology 258, 686-688.
68. Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, Matsui M, Kato N. (2012). Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiology of Disease 45, 610-615.